HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin

Files in This Item:
Int J Clin Oncol_2019_24_468.pdf261.82 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/76534

Title: Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin
Authors: Hamauchi, Satoshi Browse this author
Yokota, Tomoya Browse this author
Mizumachi, Takatsugu Browse this author →KAKEN DB
Onozawa, Yusuke Browse this author
Ogawa, Hirofumi Browse this author
Onoe, Tsuyoshi Browse this author
Kamijo, Tomoyuki Browse this author
Iida, Yoshiyuki Browse this author
Nishimura, Tetsuo Browse this author →KAKEN DB
Onitsuka, Tetsuro Browse this author
Yasui, Hirofumi Browse this author
Homma, Akihiro Browse this author →KAKEN DB
Keywords: Head and neck cancer
Carboplatin
Cetuximab
Chemoradiotherapy
Issue Date: 17-Jan-2019
Publisher: Springer
Journal Title: International journal of clinical oncology
Volume: 24
Issue: 5
Start Page: 468
End Page: 475
Publisher DOI: 10.1007/s10147-018-01392-9
PMID: 30656463
Abstract: Background : Locally advanced squamous cell carcinoma of the head and neck (LASCCHN) is usually treated with cisplatin (CDDP)-based chemoradiotherapy, except when patients are elderly or have renal, cardiac, or neurogenic dysfunction. This study compared the safety and efficacy of concurrent carboplatin (CBDCA) to cetuximab (Cmab) plus radiotherapy (RT) in patients ineligible for CDDP treatment. Methods : We retrospectively analyzed LASCCHN patients who received CBDCA plus RT (n = 29) or Cmab plus RT (n = 18) due to ineligibility for CDDP treatment at two Japanese institutions between August 2006 and December 2015. Results : Patients characteristics for CBDCA plus RT and Cmab plus RT were: median age, 74 and 75 years; 0-1 performance status, 90% and 100%; main primary tumor site, hypopharynx 52% (n = 15) and oropharynx 39% (n = 7); and stage IV, 90% (n = 26) and 50% (n = 9), respectively. With a median follow-up time of 60.0 months for CBDCA plus RT and 53.6 months for Cmab plus RT, 3-year locoregional control rates were 56% versus 58%, and median progression-free survival was 42.7 versus 11.6 months. CBDCA plus RT was associated with more grade 3/4 hematologic toxicities, including neutropenia and thrombocytopenia, whereas Cmab plus RT was associated with more grade 3/4 oral mucositis and radiation dermatitis. Conclusions : CBDCA or Cmab as a concurrent systemic therapy with RT is a possible treatment option for LASCCHN patients ineligible for CDDP treatment, although attention to hematological toxicity should be paid.
Rights: This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-018-01392-9
Type: article (author version)
URI: http://hdl.handle.net/2115/76534
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 本間 明宏

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University